HKG EPITHERAPEUTICS LTD Laboratory RECEIVES ACCREDITATION FROM COLLEGE OF AMERICAN PATHOLOGISTS

Hong Kong, January 12, 2022

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to HKG epiTherapeutics Ltd Laboratory, Hong Kong, based on results of recent on-site inspection as part of the CAP’s Accreditation Programs.

The accreditation for HKG epiTherapeutics Ltd Laboratory in 3/F Biotech Centre 2
11 Science Park West Avenue Hong Kong and its Cervical cancer detection test using Next Generation sequencing technology.

HKG cervical cancer detection test in unique by detecting cancer in otherwise premalignant samples using next generation sequencing and DNA methylation, developed by HKG epitherapeutics in collaboration with McGill University in Montreal Canada.

The facility’s director, Carlos J. Ruiz, MD, was advised of this national recognition and congratulated for the excellence of the services being provided, HKG epiTherapeutics Ltd Laboratory is one of more than 8000 CAP-accredited facilities worldwide.

“It is an important milestone for our company translating our discoveries to excellence in delivery of highest quality early detection clinical tests to people of Hong Kong the US and globally said Prof Moshe Szyf, the founder of HKG epiTherapeutics Ltd.

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government’s own inspection program.

During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

 Prof. Moshe Szyf, the founder of HKG Epitherapeutics, says: “ We thank the Accreditation Committee of the College of American Pathologists for its thorough review and for awarding HKG Epitherapeutics this important recognition of our excellence in clinical testing. We also congratulate our employees for their excellence and hard work leading us to this milestone. We aspire to provide the highest quality of clinical testing services.”

About HKG EPITHERAPEUTICS LTD

HKG Epitherapeutics was founded in 2016 by Prof. Moshe Szyf, a world pioneer in the exciting and rapidly emerging science of Epigenetics.

A Hong Kong company, dedicated to harnessing the untapped power and possibilities of Epigenetics (with its research and diagnostic lab in Hong Kong).